Multi-view learning to unravel the different levels underlying hepatitis B vaccine response
The immune system acts as the intricate apparatus dedicated to mounting a defence that ensures host survival from microbial threats. To engage this faceted immune response and provide protection against infectious diseases, vaccinations are the critical tool developed. However, vaccine responses are governed by levels that when interrogated separately only explain a fraction of the immune reaction. To address this knowledge gap, we conducted a feasibility study to determine if multi-view modelling can aid in gaining actionable insights on response markers shared across populations, capture the immune system diversity, and disentangle confounders. We thus sought to assess this multi-view modelling capacity on the responsiveness to Hepatitis B virus (HBV) vaccination. Seroconversion to vaccine induced antibodies against HBV surface antigen (anti-HBs) in early-converters (n=21; <2 month) and late-converters (n=9; <6 months), was defined based on the anti-HBs titres (>10IU/L). The multi-view data encompassed bulk RNA-seq, CD4+ T cell parameters (including T-cell receptor data), flow cytometry data, and clinical metadata (including age and gender). The modelling included testing single-view and multi-view joint dimensionality reductions. Multi-view joint dimensionality reduction out-performed single-view methods in terms of area under curve and balanced accuracy, confirming an increase in predictive power to be gained. The interpretation of the findings showed that age, gender, inflammation-related gene sets and pre-existing vaccine specific T-cells were associated with vaccination responsiveness. This multi-view dimensionality reduction approach complements the clinical seroconversion and all single modalities. Importantly, this modelling could identify what features predict HBV vaccine response. This methodology could be extended to other vaccination trials to identify key features regulating responsiveness.